It will be interesting to see things play out over the last 3 weeks of Q2. GC states that an R/S may not be necessary due to what data is coming out. I can't beleive this will actually make it to $2 organically with only the known milestones coming and Lympro. A MANF partnership could go a long way.

I would welcome a R/S when the pps is at .50 or higher to uplist. Knock down the outstanding shares and gear up for institutional growth.

San Diego is up next, I would hope that by that date, the PRs have already started. Time will tell. The recent ups and downs don't bother me or get me too excited b/c we all know that over the next 5 weeks, big things should happen.

Everyone have a great weekend!